Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company ...

Shares of Sun Pharmaceuticals dropped 3.5% after a court in New Jersey issued an injunction delaying the launch of its drug ...

How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Thirty out of the 41 analysts tracking the company have a 'buy' rating on the stock, seven suggest a 'hold' and four have a ...

Given the investments of around $576 million and the peak revenues potential upwards of $200 million, four years down the ...

Sun Pharmaceuticals Ltd. announced on Saturday that the US District Court of New Jersey has granted a preliminary injunction ...

According to Citi, the delay in the launch of Sun Pharma's alopecia areata drug, Leqselvi, could impact its near-term ...

Shares of Sun Pharmaceutical fell 2.64 per cent after the pharma major recently announced that the US District Court of delayed the launch of its new drug - Leqselvi.

Pharma giant, Sun Pharmaceutical's launch of its specialty drug Leqselvi in the U.S. market is in limbo as the U.S. District Court in New Jersey has issued a preliminary injunction.

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.